Project description DEENESFRITPL A novel vaccine against the SARS-CoV-2 virus There is an ongoing race towards the development of a vaccine against the SARS-CoV-2 virus. The EU-funded Prevent-nCoV project will use proprietary technology to develop a novel and scalable vaccine with proven efficacy in an animal model. The technology uniquely combines virus-like particles (VLP) and the antigen of choice produced by any expression system. The two components are mixed under physiological conditions, leading to the high-density display of the antigen on the VLP surface. Vaccine candidates will initially be tested for their virus neutralisation capacity in vitro and in preclinical infection models before proceeding with a phase I/IIa study. Show the project objective Hide the project objective Objective Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate. The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen. AdaptVac's VLP display technology has been shown to significantly improve vaccine immunogenicity, longevity and efficacy, for a wide range of viral and parasite diseases in pre-clinical studies (including flu and malaria). A unique feature of the technology is its two-component approach. The VLP is generic to all vaccines, and produced at >1g/L yields using E. coli. The disease antigen is produced in any expression system, allowing the most challenging antigens to be successfully produced. The VLP and antigen is then simply mixed, and a spontaneous, irreversible, conjugationoccurs under physiological conditions. This results in site-specific, directional, and high-density display of the antigen on the VLP surface. The antigen will be produced using ExpreS2ion's Drosophila S2 insect cells based on the trimetric spike antigen. Furthermore, E. coli and baculovirus will be tested for Spike protein variants. The vaccine candidates will be tested pre-clinically using in vitro viral neutralization assays and possibly animal challengemodels as they become available at LUMC. ExpreS2ion will develop the production processes and transfer these for GMP manufacture of the VLP and vaccine antigen, outsourced, to AGC Biologics. Finally, a phase I/IIa study will be performed at Radboud University Medical Center in the Netherlands. A surrogate marker of protection will be established by showing protection in animal models using passive transfer of participant sera, or by in vitro SARS-CoV-2 viral neutralization. This project is focused on delivering a scalable vaccine, ready for testing in the field, which has been shown to be safe in humans and effective in in vitro or animal models. Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses Keywords vaccine prevention Virus-Like Particle VLP Spike protein 2019-nCoV Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-PHE-CORONAVIRUS-2020 - Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic Call for proposal H2020-SC1-PHE-CORONAVIRUS-2020 See other projects for this call Funding Scheme RIA - Research and Innovation action Coordinator KOBENHAVNS UNIVERSITET Net EU contribution € 128 647,50 Address NORREGADE 10 1165 Kobenhavn Denmark See on map Region Danmark Hovedstaden Byen København Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 128 647,50 Participants (8) Sort alphabetically Sort by Net EU contribution Expand all Collapse all ADAPTVAC APS Denmark Net EU contribution € 1 481 250,00 Address AGERN ALLE 1 2970 Horsholm See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Nordsjælland Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 152 297,50 EBERHARD KARLS UNIVERSITAET TUEBINGEN Germany Net EU contribution € 295 897,50 Address GESCHWISTER-SCHOLL-PLATZ 72074 Tuebingen See on map Region Baden-Württemberg Tübingen Tübingen, Landkreis Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 295 897,50 Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. Universitaetsklinikum Tuebingen Germany Net EU contribution € 0,00 Address Geissweg 3 72076 Tuebingen See on map Region Baden-Württemberg Tübingen Tübingen, Landkreis Activity type Research Organisations Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data EXPRES2ION BIOTECHNOLOGIES APS Denmark Net EU contribution € 160 882,50 Address AGERN ALLE 1 2970 Horsholm See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Nordsjælland Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 160 882,50 WAGENINGEN UNIVERSITY Netherlands Net EU contribution € 66 147,50 Address DROEVENDAALSESTEEG 4 6708 PB Wageningen See on map Region Oost-Nederland Gelderland Veluwe Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 66 147,50 ACADEMISCH ZIEKENHUIS LEIDEN Netherlands Net EU contribution € 50 625,00 Address ALBINUSDREEF 2 2333 ZA Leiden See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 50 625,00 STICHTING RADBOUD UNIVERSITEIT Participation ended Netherlands Net EU contribution € 0,00 Address HOUTLAAN 4 6525 XZ Nijmegen See on map Region Oost-Nederland Gelderland Arnhem/Nijmegen Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM Netherlands Net EU contribution € 544 890,00 Address GEERT GROOTEPLEIN 10 ZUID 6525 GA Nijmegen See on map Region Oost-Nederland Gelderland Arnhem/Nijmegen Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 544 890,00
